Immunotherapy News and Research

Latest Immunotherapy News and Research

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax, a cancer immunotherapeutic "vaccine" that specifically targets the tumor blood vessels (endothelium).

9 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

Dendreon shareholders call for annual elections to increase board independence and accountability

Eighty-four percent (84%) of votes cast by shareholders at Dendreon voted in favor of a proxy proposal calling for annual election of board members, a strategy - which if enacted - would increase board independence and accountability.

6 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Cellectis, a leader of engineered CART cell therapies, and Thermo Fisher Scientific announced today that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

5 Jun 2014

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

4 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

Yoga can't be considered routine intervention for patients with asthma

Yoga has long been promoted as a method for improving physical and mental well-being. And although yoga is often suggested to asthma sufferers to help alleviate symptoms, a new study found little evidence that yoga will improve symptoms.

4 Jun 2014

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

4 Jun 2014

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology.

3 Jun 2014

Researchers examine health benefits of yoga for asthma sufferers

3 Jun 2014

New investigational immunotherapy benefits people with advanced urothelial bladder cancer

A new investigational immunotherapy MPDL3280A has been shown to shrink tumours in 43% of people (13/30) who had previously been treated for advanced urothelial bladder cancer (UBC) with a specific type of tumour (PD-L1 positive).

3 Jun 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

Northwestern Medicine allergist offers tips to fight allergies

Nasal congestion, sneezing, and itchy and watery eyes — for the nearly 50 million Americans with seasonal allergies, these are the true rites of spring

31 May 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Research roundup: Funding for safety-net hospitals; insurance competition

Dendreon shareholders call for annual elections to increase board independence and accountability

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Yoga can't be considered routine intervention for patients with asthma

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

Researchers examine health benefits of yoga for asthma sufferers

New investigational immunotherapy benefits people with advanced urothelial bladder cancer

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Northwestern Medicine allergist offers tips to fight allergies

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in